Lo Simpesse Kit
Product Images NDC 65862-866

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Lo Simpesse (NDC 65862-866). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Levonorethinyl Fig1)

Figure-1 (Levonorethinyl Fig1)
This appears to be a chart displaying percentages and numbers related to a study. The chart shows the percentage of bleeding and spotting experienced by participants with one, two, and three cycles. The chart also shows the number of days in each cycle for different groups of participants.*
FDA Label Image

Figure2 (Levonorethinyl Fig2)

Figure2 (Levonorethinyl Fig2)
This is a compilation of effect estimates from various studies conducted on the use of Combined Oral Contraceptives (COC). The studies compare the risks associated with "Ever COC use" (having used COC at any point in time) vs "Never COC use". The text shows the names of the studies, the authors and the year of publication along with the risk ratios (RR), hazard ratios (HR), and odds ratios (OR) obtained from each study. The estimates suggest that there is no significant difference in the risk of adverse effects between ever-users and never-users of COC. Additionally, there is a subsection in the text that compares the risk ratios between current COC use and never-use, showing potential increased risk associated with current use.*
FDA Label Image

Figure-3 (Levonorethinyl Fig3)

Figure-3 (Levonorethinyl Fig3)
This text appears to be a comparison of different forms of birth control methods and their effectiveness, measured by the number of pregnancies per 100 women in a year. The text mentions several forms of birth control, including implants, injections, intrauterine devices, sterilization, birth control pills, skin patches, vaginal rings with hormones, condoms, diaphragm, spermicide, withdrawal, and abstaining from sex during the most fertile days of the monthly cycle. The chart in the text shows that the number of pregnancies per 100 women in a year ranges from fewer than 1 to 85 or more, depending on the method used.*
FDA Label Image

Package Label-principal Display Panel (0.1 mg/0.02 mg and 0.01 mg (91 Tablets Pouch))

Package Label-principal Display Panel (0.1 mg/0.02 mg and 0.01 mg (91 Tablets Pouch))
FDA Label Image

Package Label-principal Display Panel (0.1 mg/0.02 mg and 0.01 mg (91 Tablets Carton))

Package Label-principal Display Panel (0.1 mg/0.02 mg and 0.01 mg (91 Tablets Carton))
FDA Label Image

Levonorethinyl Fig6

Levonorethinyl Fig6
This is a product description of the oral contraceptive drug named “Lo Simpesse”. It comes in two extended-cycle wallets with 91 tablets each. The pills contain a combination of Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol in different doses. The manufacturer of the drug is Aurobindo Pharma. The package is designed to prevent pregnancy, but it does not protect against sexually transmitted infections. The product is only available with a prescription.*
FDA Label Image

Levonorgestrel Chemical Structure (Levonorethinyl Str1)

Levonorgestrel Chemical Structure (Levonorethinyl Str1)
This text provides information about Levonorgestrel, including its chemical formula (CuHxO) and molecular weight (3124). It does not provide further details or context about Levonorgestrel itself.*
FDA Label Image

Ethinyl Estradiol Chemical Structure (Levonorethinyl Str2)

Ethinyl Estradiol Chemical Structure (Levonorethinyl Str2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.